A Phase 1b proof-of-concept study of BGE-102 in patients with obesity
Latest Information Update: 31 May 2025
At a glance
- Drugs BGE 102 (Primary)
- Indications Obesity
- Focus Adverse reactions; Proof of concept
Most Recent Events
- 31 May 2025 New trial record
- 29 May 2025 According to a Bioage labs media release, Following successful Phase 1 results, BioAge plans to initiate a Phase 1b proof-of-concept study in obesity in the second half of 2026.